August 18th 2025
Michael Haller, MD, discusses inhaled insulin’s safety, off-label use, and future role in easing type 1 diabetes management for children.
Acute and chronic complications in children with type 1 diabetes mellitus
June 1st 2023Part of the risk of developing kidney involvement begins when type 1 diabetes mellitus (T1DM) sets in and establishes itself in the patient, with up to 65% of children experiencing acute kidney injury during T1DM onset, which can further predispose to the development of future chronic kidney disease.
FDA clears algorithm-based automated insulin dosing system for T1D patients 6 years and up
May 25th 2023The Beta Bionics iLet ACE Pump and the iLet Dosing Decision software, matched with a compatible FDA-cleared integrated continuous glucose monitor, use an algorithm to determine and command insulin delivery to users.
Glucose levels are in target range at higher percentage with hybrid closed-loop system
May 16th 2023A hybrid closed-loop system can deliver glucose levels in the target range at a higher percentage of time among children aged 2 years to younger than 6 years compared to standard-care, according to a study in the New England Journal of Medicine.
Equitable access to glucose monitoring improves HbA1c levels
May 8th 2023Hemoglobin A1c improved in youths with newly diagnosed type 1 diabetes (T1D) when inclusive continuous glucose monitoring (CGM) was initiated, irrespective of ethnicity or insurance status. According to a study published in Jama Network Open, universal CGM could play a role in reducing disparities for minoritized racial and ethnic groups.
How insulin changed the way type 1 diabetes was treated in children
April 14th 2023Andrew Lam, MD, retinal surgeon, author, assistant professor, University of Massachusetts Medical School discusses the earliest treatments for type 1 diabetes in children, a topic of his new book, "The Masters of Medicine: Our Greatest Triumphs in the Race to Cure Humanity’s Deadliest Diseases," due out April 18, 2023.
FDA approves teplizumab for delay of type 1 diabetes in patients 8 years and up
November 18th 2022The US FDA announced the approval of teplizumab (Tzield), which is administered through IV infusion once daily for 14 consecutive days, for delaying the onset of stage 3 type 1 diabetes in adults and pediatric patients 8 years and older who currently have stage 2 type 1 diabetes.